8-K filing — Tenaya Therapeutics, Inc. (TNYA)
Filed: 2026-07-02 AccNo: 0001193125-26-294879 Size: 153 KB Item 1.02: Termination of a Material Definitive Agreement
Read original at edgarStocks · News reference
Tenaya Therapeutics Q2 EPS $(0.20) Misses $(0.05) Estimate, Sales $1.110M Miss $10.000M Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.05) by 300 percent. This is a 42.86 percent decrease over losses of $(0.14) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 10:39 PM
- Checked
- Aug 5, 2026, 10:39 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Tenaya Therapeutics Appoints Eric Hyllengren CFO, Effective July 13
Read original at benzingaTenaya Therapeutics To Report New Interim Data From Cohort 1 And 2 Of Ongoing MyPEAK-1 Phase 1b/2 Trial Of TN-201 Gene Therapy For Adults With MYBPC3-Associated Hypertrophic Cardiomyopathy On June 3
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today
Read original at benzinga